Stage I, II and III Small Cell Lung Cancer (SCLC)

Authored by Open Medicine, published on 2026-04-14 00:26:22.0

Limited-stage Small Cell Lung Cancer treatment with curative intent.

  1. Limited-stage SCLC (i.e. stage I–III SCLC eligible for treatment of curative intent)
    • Stage I–II (cT1-2 N0)*
      *After extensive pathological mediastinal staging.
      • Surgical resection
        Only a small proportion of SCLC patients are eligible for surgery. Surgical resection may be considered in carefully selected early-stage cases (stage I–II, cT1–2 N0) or when mixed histology with NSCLC is suspected, following thorough staging and multidisciplinary evaluation.
        • pT1-2 N0-1, R0
          • Adjuvant cisplatin–etoposide (4 cycles)
            The preferred chemotherapy regimen is cisplatin plus etoposide given every 3 weeks for four cycles, with the option to split the cisplatin dose to improve tolerability. If cisplatin is contraindicated, carboplatin–etoposide can be used, and growth factor support (G-CSF or GM-CSF) may be given to reduce hematologic toxicity.
        • N2 and/or R1-2
          • Concurrent CRT
            For most patients with T1–4 N0–3 M0 SCLC and good performance status, concurrent chemotherapy and thoracic radiotherapy is the standard treatment, ideally started early (by cycle 1–2), with 45 Gy given twice daily over 3 weeks as the preferred regimen or 66 Gy once daily as an alternative.
            • No progression**
              **The role of PCI is not well defined in patients with stage I-II SCLC, patients > 70 years of age and frail patients. In these cases, shared decision-making is recommended.
              • PS 0-1 Age ≤ 70
                • PCI
                  Prophylactic cranial irradiation (PCI) reduces the risk of symptomatic brain metastases and improves survival, and is recommended for patients with good performance status (PS 0–1) who respond to chemoradiotherapy, with consideration also for PS 2 patients.
              • PS 2 Age ≤ 70
                • PCI
                  Prophylactic cranial irradiation (PCI) reduces the risk of symptomatic brain metastases and improves survival, and is recommended for patients with good performance status (PS 0–1) who respond to chemoradiotherapy, with consideration also for PS 2 patients.
              • Age > 70 or frail
                • Shared decision making for PCI
                  Benefit of prophylactic cranial irradiation (PCI) is less clear in early-stage disease, older patients (>70), or those who are frail, where shared decision-making is advised.
    • Stage I–III (cT1-4 N0-3 M0)
      • PS 0-1
        • Concurrent CRT
          For most patients with T1–4 N0–3 M0 SCLC and good performance status, concurrent chemotherapy and thoracic radiotherapy is the standard treatment, ideally started early (by cycle 1–2), with 45 Gy given twice daily over 3 weeks as the preferred regimen or 66 Gy once daily as an alternative.
          • No progression**
            **The role of PCI is not well defined in patients with stage I-II SCLC, patients > 70 years of age and frail patients. In these cases, shared decision-making is recommended.
            • PS 0-1 Age ≤ 70
              • PCI
                Prophylactic cranial irradiation (PCI) reduces the risk of symptomatic brain metastases and improves survival, and is recommended for patients with good performance status (PS 0–1) who respond to chemoradiotherapy, with consideration also for PS 2 patients.
            • PS 2 Age ≤ 70
              • PCI
                Prophylactic cranial irradiation (PCI) reduces the risk of symptomatic brain metastases and improves survival, and is recommended for patients with good performance status (PS 0–1) who respond to chemoradiotherapy, with consideration also for PS 2 patients.
            • Age > 70 or frail
              • Shared decision making for PCI
                Benefit of prophylactic cranial irradiation (PCI) is less clear in early-stage disease, older patients (>70), or those who are frail, where shared decision-making is advised.
      • PS ≥ 2
        • Sequential CRT
          Sequential chemoradiotherapy may be used when patients cannot tolerate concurrent treatment due to frailty, comorbidities, or disease burden, and timing may be delayed if necessary based on patient condition or organ risk constraints.
          • No progression**
            **The role of PCI is not well defined in patients with stage I-II SCLC, patients > 70 years of age and frail patients. In these cases, shared decision-making is recommended.
            • PS 0-1 Age ≤ 70
              • PCI
                Prophylactic cranial irradiation (PCI) reduces the risk of symptomatic brain metastases and improves survival, and is recommended for patients with good performance status (PS 0–1) who respond to chemoradiotherapy, with consideration also for PS 2 patients.
            • PS 2 Age ≤ 70
              • PCI
                Prophylactic cranial irradiation (PCI) reduces the risk of symptomatic brain metastases and improves survival, and is recommended for patients with good performance status (PS 0–1) who respond to chemoradiotherapy, with consideration also for PS 2 patients.
            • Age > 70 or frail
              • Shared decision making for PCI
                Benefit of prophylactic cranial irradiation (PCI) is less clear in early-stage disease, older patients (>70), or those who are frail, where shared decision-making is advised.
tosprivacySmall-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upRadiation Therapy for Small-Cell Lung Cancer: ASCO Guideline Endorsement of an ASTRO GuidelineASTRO Guideline on Radiation Therapy for Small Cell Lung Cancer